|Dublin Core||PKP Metadata Items||Metadata for this Document|
|1.||Title||Title of document||Infanrix hexa and sudden death: a review of the periodic safety update reports submitted to the European Medicines Agency|
|2.||Creator||Author's name, affiliation, country||Jacob Puliyel; St Stephens Hospital, Delhi 110054, India|
There have been a number of spontaneous reports of sudden unexpected death soon after the administration of Infanrix hexa (combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis and Haemophilus influenza type B vaccine). The manufacturer, GlaxoSmithKline (GSK), submits confidential periodic safety update reports (PSURs) on Infanrix hexa to the European Medicines Agency (EMA). The latest is the PSUR 19. Each PSUR contains an analysis of observed/expected sudden deaths, which shows that the number of observed deaths soon after immunisation is lower than that expected by chance.
This commentary focuses on that aspect of the PSUR which has a bearing on policy decisions. We analysed the data provided in the PSURs. It is apparent that the deaths acknowledged in the PSUR 16 were deleted from the PSUR 19. The number of observed deaths soon after vaccination among children older than one year was significantly higher than that expected by chance once the deleted deaths were restored and included in the analysis.
The manufacturer must explain the figures that have been submitted to the regulatory authorities. The procedures undertaken by the EMA to evaluate the manufacturer's claims in the PSUR need to be reviewed. The Drugs Controller General of India nearly automatically accepts drugs and vaccines approved by the EMA. There is a need to reappraise the reliance on due diligence by the EMA.
|5.||Publisher||Organizing agency, location||Forum for Medical Ethics Society|
|8.||Type||Status & genre|
|9.||Format||File format||HTML , PDF|
|10.||Identifier||Uniform Resource Identifier||https://ijme.in/articles/infanrix-hexa-and-sudden-death-a-review-of-the-periodic-safety-update-reports-submitted-to-the-european-medicines-agency/|
|11.||Source||Title; vol., no. (year)||Indian Journal of Medical Ethics;: Can medical ethics be “neutral”?|
|14.||Coverage||Geo-spatial location, chronological period, research sample (gender, age, etc.)|
|15.||Rights||Copyright and permissions||
All articles published in IJME are available on its website free of charge. The copyright for published material belongs to IJME/FMES. IJME freely permits the reprint (or reproduction on a website) of articles from the journal, as long as this is for non-commercial use and appropriate credit is given to the author and the journal and publication details are mentioned. The commercial use of our content can be made only after obtaining permission from and on payment to IJME. This is intended to support production of the journal.